Astellas Pharma Inc. - ADR
ALPMY
Get informed when a big investor buys or sells
+ FollowMarket Cap$28.58B
Close$
$48.53
204.3% upside
Current Fair Value
204.3% upsideUndervalued by 204.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $28.58 Billion |
|---|---|
| Enterprise Value | $371.47 Billion |
| Dividend Yield | $0.45 (3.14%) |
| Earnings per Share | $172.56 |
| Beta | 0.09 |
| Outstanding Shares | 1,791,933,000 |
Return
| Return on Equity | 15.76% |
|---|---|
| Return on Assets | 8.29% |
| Return on Invested Capital | 17.25% |
Valuation & Multiples
| P/E Ratio | 12.33 |
|---|---|
| PEG | 11.23 |
| Price to Sales | 0.02 |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | 0.2 |
| Enterprise Value to EBIT | 0.88 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 1.58 |
| Debt to Equity | 0.3 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.34
Average shareholder expectationRevenue Estimate
$3.47 B
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$0.39
Average shareholder expectationRevenue Estimate
$3.70 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Astellas Pharma Inc.
14,099 employees
CEO: Kenji Yasukawa Astellas Pharma Inc., a venerable Japanese pharmaceutical enterprise established in 1923 and headquartered in Tokyo, operates globally in the research, development, manufacturing, and commercialization of a diverse range of medications. ...